-
1
-
-
47749117650
-
Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial
-
Tatti S, Swinehart J, Thielert C, Tawfik H, Mescheder A, Beutner K. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008 : 111 (6 1371 1379.
-
(2008)
Obstet Gynecol
, vol.111
, Issue.6
, pp. 1371-1379
-
-
Tatti, S.1
Swinehart, J.2
Thielert, C.3
Tawfik, H.4
Mescheder, A.5
Beutner, K.6
-
2
-
-
34548032104
-
Prophylactic human papillomavirus vaccines: Potential for sea change
-
Ferenczy A, Franco EL. Prophylactic human papillomavirus vaccines: potential for sea change. Expert Rev Vaccines 2007 : 6 (4 511 525.
-
(2007)
Expert Rev Vaccines
, vol.6
, Issue.4
, pp. 511-525
-
-
Ferenczy, A.1
Franco, E.L.2
-
3
-
-
38449105799
-
The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries
-
Kjaer S, Tran T, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007 : 196 (10 1447 1454.
-
(2007)
J Infect Dis
, vol.196
, Issue.10
, pp. 1447-1454
-
-
Kjaer, S.1
Tran, T.2
Sparen, P.3
-
4
-
-
0037421589
-
Epidemiologic classification of human papillomavirus types associated with cervical cancer
-
Munoz N, Bosch F, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 : 348 (6 518 527.
-
(2003)
N Engl J Med
, vol.348
, Issue.6
, pp. 518-527
-
-
Munoz, N.1
Bosch, F.2
De Sanjose, S.3
-
5
-
-
0032840918
-
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
-
Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 : 189 (1 12 19.
-
(1999)
J Pathol
, vol.189
, Issue.1
, pp. 12-19
-
-
Walboomers, J.1
Jacobs, M.2
Manos, M.3
-
6
-
-
0023815225
-
Epidemiology of genital human papillomavirus infection
-
Koutsky L, Galloway D, Holmes K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988 : 10 : 122 163.
-
(1988)
Epidemiol Rev
, vol.10
, pp. 122-163
-
-
Koutsky, L.1
Galloway, D.2
Holmes, K.3
-
7
-
-
33748761925
-
Chapter 2: The burden of HPV-related cancers
-
Parkin D, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006 : 24 : 11 25.
-
(2006)
Vaccine
, vol.24
, pp. 11-25
-
-
Parkin, D.1
Bray, F.2
-
8
-
-
0037243946
-
Human papillomavirus and cervical cancer
-
Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003 : 16 (1 1 17.
-
(2003)
Clin Microbiol Rev
, vol.16
, Issue.1
, pp. 1-17
-
-
Burd, E.1
-
9
-
-
2942567871
-
Classification of papillomaviruses
-
de Villiers E, Fauquet C, Broker T, Bernard H, zur Hausen H. Classification of papillomaviruses. Virology 2004 : 324 (1 17 27.
-
(2004)
Virology
, vol.324
, Issue.1
, pp. 17-27
-
-
De Villiers, E.1
Fauquet, C.2
Broker, T.3
Bernard, H.4
Zur Hausen, H.5
-
10
-
-
14744297766
-
The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses
-
Bernard H. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005 : 32 : 1 6.
-
(2005)
J Clin Virol
, vol.32
, pp. 1-6
-
-
Bernard, H.1
-
11
-
-
0034600355
-
Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis
-
Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000 : 92 (9 690 698.
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.9
, pp. 690-698
-
-
Hausen, H.1
-
12
-
-
17444368112
-
The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: Consequences for clinical management
-
Brinkman J, Caffrey A, Muderspach L, Roman L, Kast W. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol 2005 : 26 (2 129.
-
(2005)
Eur J Gynaecol Oncol
, vol.26
, Issue.2
, pp. 129
-
-
Brinkman, J.1
Caffrey, A.2
Muderspach, L.3
Roman, L.4
Kast, W.5
-
13
-
-
0027428414
-
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
-
Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993 : 67 (12 6929 6936.
-
(1993)
J Virol
, vol.67
, Issue.12
, pp. 6929-6936
-
-
Kirnbauer, R.1
Taub, J.2
Greenstone, H.3
-
14
-
-
0021986880
-
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
-
Schwarz E, Freese U, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985 : 314 (6006 111 114.
-
(1985)
Nature
, vol.314
, Issue.6006
, pp. 111-114
-
-
Schwarz, E.1
Freese, U.2
Gissmann, L.3
-
15
-
-
0028900490
-
Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis
-
Jeon S, Lambert P. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci 1995 : 92 (5 1654 1658.
-
(1995)
Proc Natl Acad Sci
, vol.92
, Issue.5
, pp. 1654-1658
-
-
Jeon, S.1
Lambert, P.2
-
16
-
-
63149127312
-
-
Gardasil® package insert. Whitehouse Station, NJ: Merck & Co.
-
Gardasil® package insert. Whitehouse Station, NJ : Merck & Co., 2007.
-
(2007)
-
-
-
17
-
-
63149104610
-
-
Cervarix® package insert. Rixensart, Belgium: GlaxoSmithKline Biologicals
-
Cervarix® package insert. Rixensart, Belgium : GlaxoSmithKline Biologicals, 2007.
-
(2007)
-
-
-
18
-
-
33746096523
-
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
-
Giannini S, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006 : 24 (33-34 5937 5949.
-
(2006)
Vaccine
, vol.24
, Issue.3334
, pp. 5937-5949
-
-
Giannini, S.1
Hanon, E.2
Moris, P.3
-
19
-
-
34248365967
-
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
-
Garland S, Hernandez-Avila M, Wheeler C, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 : 356 (19 1928 1943.
-
(2007)
N Engl J Med
, vol.356
, Issue.19
, pp. 1928-1943
-
-
Garland, S.1
Hernandez-Avila, M.2
Wheeler, C.3
-
20
-
-
34248326338
-
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
-
Future II Study Group.
-
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 : 356 (19 1915 1927.
-
(2007)
N Engl J Med
, vol.356
, Issue.19
, pp. 1915-1927
-
-
-
21
-
-
34250850161
-
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial
-
Paavonen J, Jenkins D, Bosch F, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 : 369 (9580 2161 2170.
-
(2007)
Lancet
, vol.369
, Issue.9580
, pp. 2161-2170
-
-
Paavonen, J.1
Jenkins, D.2
Bosch, F.3
-
22
-
-
33845273878
-
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
-
Villa L, Costa R, Petta C, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 : 95 (11 1459 1466.
-
(2006)
Br J Cancer
, vol.95
, Issue.11
, pp. 1459-1466
-
-
Villa, L.1
Costa, R.2
Petta, C.3
-
23
-
-
33646058566
-
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial
-
Harper D, Franco E, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 : 367 (9518 1247 1255.
-
(2006)
Lancet
, vol.367
, Issue.9518
, pp. 1247-1255
-
-
Harper, D.1
Franco, E.2
Wheeler, C.3
-
24
-
-
50049134898
-
Cervical cancer vaccination indications, efficacy, and side effects
-
Bayas J, Costas L, Muñoz A. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol Oncol 2008 : 110 (3 Suppl 2 S11 14.
-
(2008)
Gynecol Oncol
, vol.110
, Issue.32
-
-
Bayas, J.1
Costas, L.2
Muñoz, A.3
-
25
-
-
0025331023
-
Antibody-mediated neutralization in vivo of infectious papillomaviruses
-
Christensen N, Kreider J. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990 : 64 (7 3151 3156.
-
(1990)
J Virol
, vol.64
, Issue.7
, pp. 3151-3156
-
-
Christensen, N.1
Kreider, J.2
-
26
-
-
0029990266
-
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
-
Roden R, Hubbert N, Kirnbauer R, Christensen N, Lowy D, Schiller J. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996 : 70 (5 3298 3301.
-
(1996)
J Virol
, vol.70
, Issue.5
, pp. 3298-3301
-
-
Roden, R.1
Hubbert, N.2
Kirnbauer, R.3
Christensen, N.4
Lowy, D.5
Schiller, J.6
-
27
-
-
0031579249
-
Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions
-
Liu W, Gissmann L, Sun X, et al. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 1997 : 227 (2 474 483.
-
(1997)
Virology
, vol.227
, Issue.2
, pp. 474-483
-
-
Liu, W.1
Gissmann, L.2
Sun, X.3
-
28
-
-
0029841214
-
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
-
Roden R, Greenstone H, Kirnbauer R, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996 : 70 (9 5875 5883.
-
(1996)
J Virol
, vol.70
, Issue.9
, pp. 5875-5883
-
-
Roden, R.1
Greenstone, H.2
Kirnbauer, R.3
-
29
-
-
0034630951
-
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
-
Roden R, Yutzy W, Fallon R, Inglis S, Lowy D, Schiller J. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000 : 270 (2 254 257.
-
(2000)
Virology
, vol.270
, Issue.2
, pp. 254-257
-
-
Roden, R.1
Yutzy, W.2
Fallon, R.3
Inglis, S.4
Lowy, D.5
Schiller, J.6
-
30
-
-
43049160856
-
The future of vaccines for cervical cancer
-
Huh W, Roden R. The future of vaccines for cervical cancer. Gynecol Oncol 2008 : 109 (2S 48 56.
-
(2008)
Gynecol Oncol
, vol.109
, Issue.2
, pp. 48-56
-
-
Huh, W.1
Roden, R.2
-
32
-
-
34547912100
-
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial
-
753.
-
Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 : 298 (7 743 753.
-
(2007)
JAMA
, vol.298
, Issue.7
, pp. 743
-
-
Hildesheim, A.1
Herrero, R.2
Wacholder, S.3
-
33
-
-
34347339665
-
Therapeutic vaccination for HPV induced cervical cancers
-
Brinkman J, Hughes S, Stone P, et al. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007 : 23 (4 337 352.
-
(2007)
Dis Markers
, vol.23
, Issue.4
, pp. 337-352
-
-
Brinkman, J.1
Hughes, S.2
Stone, P.3
-
34
-
-
36849045276
-
Mini review: Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions
-
Kanodia S, Da Silva D, Kast W, Los Angeles C. Mini review: recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008 : 122 247 259.
-
(2008)
Int J Cancer
, vol.122
, pp. 247-259
-
-
Kanodia, S.1
Da Silva, D.2
Kast, W.3
Los Angeles, C.4
-
35
-
-
0036644556
-
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides 1
-
Zwaveling S, Mota S, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides 1. J Immunol 2002 : 169 (1 350 358.
-
(2002)
J Immunol
, vol.169
, Issue.1
, pp. 350-358
-
-
Zwaveling, S.1
Mota, S.2
Nouta, J.3
-
36
-
-
0031712034
-
Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
-
Steller M. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998 : 4 (9 2103 2109.
-
(1998)
Clin Cancer Res
, vol.4
, Issue.9
, pp. 2103-2109
-
-
Steller, M.1
-
37
-
-
0033813525
-
A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
-
Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000 : 6 (9 3406 3416.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.9
, pp. 3406-3416
-
-
Muderspach, L.1
Wilczynski, S.2
Roman, L.3
-
38
-
-
43049181216
-
Immunotherapy of established papillomavirus-induced (pre-) malignant lesions in mice, rabbits, and patients
-
Melief C. Immunotherapy of established papillomavirus-induced (pre-) malignant lesions in mice, rabbits, and patients. Ann Oncol 2006 : 17 (3 iii28.
-
(2006)
Ann Oncol
, vol.17
, Issue.3
-
-
Melief, C.1
-
39
-
-
0345742585
-
Cytotoxic-t-lymphocyte human papillomavirus type 16 E5 Peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice
-
Chen Y, Lin C, Tsao Y, Chen S. Cytotoxic-t-lymphocyte human papillomavirus type 16 E5 Peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol 2004 : 78 (3 1333 1343.
-
(2004)
J Virol
, vol.78
, Issue.3
, pp. 1333-1343
-
-
Chen, Y.1
Lin, C.2
Tsao, Y.3
Chen, S.4
-
40
-
-
27944502138
-
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
-
Torréns I, Mendoza O, Batte A, et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 2005 : 23 (50 5768 5774.
-
(2005)
Vaccine
, vol.23
, Issue.50
, pp. 5768-5774
-
-
Torréns, I.1
Mendoza, O.2
Batte, A.3
-
41
-
-
33744505292
-
Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion
-
Daftarian P, Mansour M, Benoit A, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006 : 24 (24 5235 5244.
-
(2006)
Vaccine
, vol.24
, Issue.24
, pp. 5235-5244
-
-
Daftarian, P.1
Mansour, M.2
Benoit, A.3
-
42
-
-
34447265731
-
Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides
-
Daftarian P, Mansour M, Pohajdak B, et al. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides. J Transl Med 2007 : 5 (1 26 33.
-
(2007)
J Transl Med
, vol.5
, Issue.1
, pp. 26-33
-
-
Daftarian, P.1
Mansour, M.2
Pohajdak, B.3
-
43
-
-
30344457591
-
Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6?/mE7/TBhsp70? fusion protein vaccine in an animal model
-
Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6?/mE7/TBhsp70? fusion protein vaccine in an animal model. Immunol Lett 2006 : 102 (2 191 201.
-
(2006)
Immunol Lett
, vol.102
, Issue.2
, pp. 191-201
-
-
Qian, X.1
Lu, Y.2
Liu, Q.3
Chen, K.4
Zhao, Q.5
Song, J.6
-
44
-
-
0033652876
-
Natural autoantibodies against heat-shock proteins hsp70 and gp96: Implications for immunotherapy using heat-shock proteins
-
Menoret A, Chandawarkar R, Srivastava P. Natural autoantibodies against heat-shock proteins hsp70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology 2000 : 101 (3 364 370.
-
(2000)
Immunology
, vol.101
, Issue.3
, pp. 364-370
-
-
Menoret, A.1
Chandawarkar, R.2
Srivastava, P.3
-
45
-
-
0034113617
-
HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
-
Asea A, Kraeft S, Kurt-Jones E, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000 : 6 : 435 442.
-
(2000)
Nat Med
, vol.6
, pp. 435-442
-
-
Asea, A.1
Kraeft, S.2
Kurt-Jones, E.3
-
46
-
-
0033507088
-
The study on the expression of membrane HSP70 protein in H22 cell and its immunoprotective mechanism against carcinoma
-
Wu W, Liu K, Xie Q, Wu H. The study on the expression of membrane HSP70 protein in H22 cell and its immunoprotective mechanism against carcinoma. J Exp Clin Cancer Res 1999 : 18 (4 543 548.
-
(1999)
J Exp Clin Cancer Res
, vol.18
, Issue.4
, pp. 543-548
-
-
Wu, W.1
Liu, K.2
Xie, Q.3
Wu, H.4
-
47
-
-
34548128005
-
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
-
Einstein M, Kadish A, Burk R, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007 : 106 (3 453 460.
-
(2007)
Gynecol Oncol
, vol.106
, Issue.3
, pp. 453-460
-
-
Einstein, M.1
Kadish, A.2
Burk, R.3
-
48
-
-
25144480814
-
HspE7 treatment of pediatric recurrent respiratory papillomatosis: Final results of an open-label trial
-
Derkay C, Smith R, McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005 : 114 (9 730 737.
-
(2005)
Ann Otol Rhinol Laryngol
, vol.114
, Issue.9
, pp. 730-737
-
-
Derkay, C.1
Smith, R.2
McClay, J.3
-
49
-
-
0036114412
-
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts
-
Goldstone S, et al. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 2002 : 45 (4 502 507.
-
(2002)
Dis Colon Rectum
, vol.45
, Issue.4
, pp. 502-507
-
-
Goldstone, S.1
-
50
-
-
3142766176
-
HspE7 treatment of high-grade anal dysplasia: Final results of an open-label trial and interim long-term follow-up
-
Paris, France.
-
Palefsky J, Goldstone S, Neefe J. HspE7 treatment of high-grade anal dysplasia: final results of an open-label trial and interim long-term follow-up. 20th International Papillomavirus Conference, 2002, Paris, France.
-
(2002)
20th International Papillomavirus Conference
-
-
Palefsky, J.1
Goldstone, S.2
Neefe, J.3
-
51
-
-
2442515370
-
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
-
Corona Gutierrez C, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004 : 15 (5 421 431.
-
(2004)
Hum Gene Ther
, vol.15
, Issue.5
, pp. 421-431
-
-
Corona Gutierrez, C.1
Tinoco, A.2
Navarro, T.3
-
52
-
-
33646817087
-
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine
-
García-Hernández E, González-Sánchez J, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006 : 13 : 592 597.
-
(2006)
Cancer Gene Ther
, vol.13
, pp. 592-597
-
-
García-Hernández, E.1
González-Sánchez, J.2
Andrade-Manzano, A.3
-
53
-
-
0032546352
-
Dendritic cells and the control of immunity
-
Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998 : 392 : 245 252.
-
(1998)
Nature
, vol.392
, pp. 245-252
-
-
Banchereau, J.1
Steinman, R.2
-
54
-
-
0030840111
-
Dendritic cells as adjuvants for immune-mediated resistance to tumors
-
Schuler G, Steinman R. Dendritic cells as adjuvants for immune-mediated resistance to tumors, J Exp Med 1997 : 186 (8 1183 1187.
-
(1997)
J Exp Med
, vol.186
, Issue.8
, pp. 1183-1187
-
-
Schuler, G.1
Steinman, R.2
-
55
-
-
0032754286
-
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
-
Dhodapkar M, Steinman R, Sapp M, Desai H, Fossella C, Karasovsky J. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999 : 104 : 173 180.
-
(1999)
J Clin Invest
, vol.104
, pp. 173-180
-
-
Dhodapkar, M.1
Steinman, R.2
Sapp, M.3
Desai, H.4
Fossella, C.5
Karasovsky, J.6
-
56
-
-
0034023485
-
Mature dendritic cells boost functionally superior CD8+ T-cell responses in humans without foreign helper epitopes
-
R14.
-
Dhodapkar M, Krasovsky J, Steinman R, Bhardwaj N. Mature dendritic cells boost functionally superior CD8+ T-cell responses in humans without foreign helper epitopes. J Clin Invest 2000 : 105 : R9 R14.
-
(2000)
J Clin Invest
, vol.105
-
-
Dhodapkar, M.1
Krasovsky, J.2
Steinman, R.3
Bhardwaj, N.4
-
57
-
-
0030026776
-
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
-
Hsu F, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996 : 2 (1 52 58.
-
(1996)
Nat Med
, vol.2
, Issue.1
, pp. 52-58
-
-
Hsu, F.1
Benike, C.2
Fagnoni, F.3
-
58
-
-
0031941423
-
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
-
Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells. Nat Med 1998 : 4 (3 328 332.
-
(1998)
Nat Med
, vol.4
, Issue.3
, pp. 328-332
-
-
Nestle, F.1
Alijagic, S.2
Gilliet, M.3
-
59
-
-
0033405438
-
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
-
Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 : 190 (11 1669 1678.
-
(1999)
J Exp Med
, vol.190
, Issue.11
, pp. 1669-1678
-
-
Thurner, B.1
Haendle, I.2
Roder, C.3
-
60
-
-
32644462764
-
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
-
Santin A, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006 : 100 (3 469 478.
-
(2006)
Gynecol Oncol
, vol.100
, Issue.3
, pp. 469-478
-
-
Santin, A.1
Bellone, S.2
Palmieri, M.3
-
62
-
-
33644888264
-
An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response
-
Öhlschläger P, Pes M, Osen W, et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006 : 24 (15 2880 2893.
-
(2006)
Vaccine
, vol.24
, Issue.15
, pp. 2880-2893
-
-
Öhlschläger, P.1
Pes, M.2
Osen, W.3
-
63
-
-
34047158832
-
The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors
-
Brinkman J, Xu X, Kast W. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 2007 : 25 (17 3437 3444.
-
(2007)
Vaccine
, vol.25
, Issue.17
, pp. 3437-3444
-
-
Brinkman, J.1
Xu, X.2
Kast, W.3
-
65
-
-
34248205600
-
HIV vaccine efficacy trials: Towards the future of HIV prevention
-
Kim D, Elizaga M, Duerr A. HIV vaccine efficacy trials: towards the future of HIV prevention. Infect Dis Clin North Am 2007 : 21 (1 201 217.
-
(2007)
Infect Dis Clin North Am
, vol.21
, Issue.1
, pp. 201-217
-
-
Kim, D.1
Elizaga, M.2
Duerr, A.3
-
66
-
-
33749337860
-
A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease
-
Bungener L, de Mare A, de Vries-Idema J, et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 2006 : 11 (6 717 727.
-
(2006)
Antivir Ther
, vol.11
, Issue.6
, pp. 717-727
-
-
Bungener, L.1
De Mare, A.2
De Vries-Idema, J.3
-
67
-
-
0036894973
-
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer 1
-
Kaufmann A, Stern P, Rankin E, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer 1. Clin Cancer Res 2002 : 8 : 3676 3685.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3676-3685
-
-
Kaufmann, A.1
Stern, P.2
Rankin, E.3
-
68
-
-
63149123489
-
-
Transgene. Available at:. Accessed October 3, 2008.
-
Transgene. TG 4001/R3484 (MVA-HPV-IL2). 2006. Available at: http://www.transgene.fr/us/product-pipeline/iframe-mva-hpv-il2.htm. Accessed October 3, 2008.
-
(2006)
TG 4001/R3484 (MVA-HPV-IL2).
-
-
-
69
-
-
28244455880
-
A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors
-
Bermudez-Humaran L, Cortes-Perez N, Lefevre F, et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005 : 175 (11 7297 7302.
-
(2005)
J Immunol
, vol.175
, Issue.11
, pp. 7297-7302
-
-
Bermudez-Humaran, L.1
Cortes-Perez, N.2
Lefevre, F.3
-
70
-
-
33646413939
-
Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice
-
Qian J, Dong Y, Pang Y, et al. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006 : 118 (12 3022 3029.
-
(2006)
Int J Cancer
, vol.118
, Issue.12
, pp. 3022-3029
-
-
Qian, J.1
Dong, Y.2
Pang, Y.3
-
71
-
-
36248945563
-
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
-
Kaufmann A, Nieland J, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007 : 121 (12 2794 2800.
-
(2007)
Int J Cancer
, vol.121
, Issue.12
, pp. 2794-2800
-
-
Kaufmann, A.1
Nieland, J.2
Jochmus, I.3
-
72
-
-
0037019901
-
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
-
de Jong A, O'Neill T, Khan A, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002 : 20 (29-30 3456 3464.
-
(2002)
Vaccine
, vol.20
, Issue.29-30
, pp. 3456-3464
-
-
De Jong, A.1
O'Neill, T.2
Khan, A.3
-
73
-
-
33845782389
-
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species
-
Gambhira R, Gravitt P, Bossis I, Stern P, Viscidi R, Roden R. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 2006 : 66 (23 11120 11124.
-
(2006)
Cancer Res
, vol.66
, Issue.23
, pp. 11120-11124
-
-
Gambhira, R.1
Gravitt, P.2
Bossis, I.3
Stern, P.4
Viscidi, R.5
Roden, R.6
|